Detalhe da pesquisa
1.
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
Biol Blood Marrow Transplant
; 25(10): 2002-2007, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31260802
2.
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Blood
; 130(21): 2243-2250, 2017 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28924018
3.
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
J Clin Oncol
; 41(15): 2815-2826, 2023 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36888930
4.
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
Leuk Lymphoma
; 63(6): 1375-1386, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35014928
5.
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
Leuk Res
; 97: 106432, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32911375
6.
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
Leukemia
; 34(3): 787-798, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31628428